1. Home
  2. Directory
  3. Maryland
  4. Towson
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1487073136

CHRISTINE NWANNEKA OKWESILI MD
Prescription History 1487073136
Internal Medicine - Infectious Disease in Towson, MD


Quality Rating: 89.25 out of 100 score

NPI Status: Active since April 09, 2014

Contact Information

7505 OSLER DR STE 214
TOWSON, MD
ZIP 21204
Phone: (410) 427-2588
Fax: (410) 427-2587

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for CHRISTINE NWANNEKA OKWESILI MD, an active Infectious Disease specialist practicing in Towson, MD. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 153 documented patient claims. Among these therapy options, the most frequently utilized medication is Daptomycin, which accounts for 44 claims alone.

Medication Index

C
D
S
U
No matching medications currently found on file.

Cefepime Hcl

Generic Formulation: Cefepime HclSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 104
MD State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills19.1
Peer Average Days Supply91
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,537.09 across this reporting matrix range.

Provider Avg Cost Per Claim

$443.36

State Avg Cost Per Claim

$187.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.

Therapeutic Applications

Cefepime is used to treat a wide variety of bacterial infections. This medication belongs to a class of drugs known as cephalosporin antibiotics. It works by stopping the growth of bacteria.

Ceftriaxone

Generic Formulation: Ceftriaxone SodiumSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 29
30-Day Fills 29.0
Days Supply 175
MD State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.3
Peer Average Days Supply95
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 45.0% more claims than the standard regional baseline profile for MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $673.23 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.21

State Avg Cost Per Claim

$82.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears.

Therapeutic Applications

Ceftriaxone is used to treat a wide variety of bacterial infections. This medication belongs to a class of drugs known as cephalosporin antibiotics. It works by stopping the growth of bacteria. This drug is not recommended for use in newborns with high blood bilirubin levels and premature infants due to increased risk of side effects. Ask the doctor or pharmacist for details.

Daptomycin

Generic Formulation: DaptomycinSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 44
30-Day Fills 44.0
Days Supply 287
MD State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills18.0
Peer Average Days Supply103
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 158.8% higher than the standard regional baseline profile for MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,739.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$198.64

State Avg Cost Per Claim

$1,005.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclic lipopeptide antibiotic that inhibits GRAM-POSITIVE BACTERIA.

Therapeutic Applications

This medication is an antibiotic used to treat serious bacterial infections. It works by stopping the growth of bacteria. This medication is not recommended for use in children younger than 12 months due to possible risk of serious side effects.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 19
30-Day Fills 26.0
Days Supply 760
MD State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills25.8
Peer Average Days Supply353
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $820.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$43.20

State Avg Cost Per Claim

$6.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Unasyn

Generic Formulation: Ampicillin Sod/Sulbactam SodSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 44
30-Day Fills 44.0
Days Supply 99
MD State Average Benchmarks
Peer Average Claims--
Peer Average 30-Day Fills--
Peer Average Days Supply--

Provider Avg Cost Per Claim

$126.43

State Avg Cost Per Claim

--

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to treat a wide variety of bacterial infections. It is known as a penicillin-type antibiotic. It works by stopping the growth of bacteria.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like CHRISTINE NWANNEKA OKWESILI MD provides transparency into local medical care patterns within Towson, MD.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Infectious Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.